Annual Cash & Cash Equivalents
$10.87 M
+$2.19 M+25.21%
December 31, 2023
Summary
- As of February 8, 2025, FRTX annual cash & cash equivalents is $10.87 million, with the most recent change of +$2.19 million (+25.21%) on December 31, 2023.
- During the last 3 years, FRTX annual cash & cash equivalents has fallen by -$19.25 million (-63.91%).
- FRTX annual cash & cash equivalents is now -77.03% below its all-time high of $47.32 million, reached on December 1, 2010.
Performance
FRTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$10.87 M
-$1.15 M-9.58%
December 31, 2023
Summary
- As of February 8, 2025, FRTX quarterly cash and cash equivalents is $10.87 million, with the most recent change of -$1.15 million (-9.58%) on December 31, 2023.
- Over the past year, FRTX quarterly cash and cash equivalents has dropped by -$1.15 million (-9.58%).
- FRTX quarterly cash and cash equivalents is now -84.58% below its all-time high of $70.47 million, reached on March 1, 2012.
Performance
FRTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
FRTX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +25.2% | -9.6% |
| 3 y3 years | -63.9% | -9.6% |
| 5 y5 years | -8.4% | -9.6% |
FRTX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -59.6% | +25.2% | -59.6% | +25.2% |
| 5 y | 5-year | -63.9% | +50.3% | -68.8% | +52.5% |
| alltime | all time | -77.0% | +2073.6% | -84.6% | +2073.6% |
Fresh Tracks Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2023 | $10.87 M(+25.2%) | $10.87 M(-9.6%) |
| Sep 2023 | - | $12.02 M(+34.3%) |
| Jun 2023 | - | $8.95 M(-16.9%) |
| Mar 2023 | - | $10.76 M(+24.0%) |
| Dec 2022 | $8.68 M(-67.7%) | $8.68 M(-22.8%) |
| Sep 2022 | - | $11.25 M(-22.3%) |
| Jun 2022 | - | $14.48 M(-16.2%) |
| Mar 2022 | - | $17.29 M(-35.7%) |
| Dec 2021 | $26.88 M(-10.7%) | - |
| Dec 2021 | - | $26.88 M(+25.7%) |
| Sep 2021 | - | $21.38 M(-12.4%) |
| Jun 2021 | - | $24.41 M(-29.8%) |
| Mar 2021 | - | $34.78 M(+15.5%) |
| Dec 2020 | $30.11 M(+316.4%) | $30.11 M(+49.3%) |
| Sep 2020 | - | $20.17 M(-6.5%) |
| Jun 2020 | - | $21.57 M(+202.7%) |
| Mar 2020 | - | $7.13 M(-1.5%) |
| Dec 2019 | $7.23 M(-39.1%) | $7.23 M(+0.1%) |
| Sep 2019 | - | $7.22 M(-33.2%) |
| Jun 2019 | - | $10.81 M(-4.0%) |
| Mar 2019 | - | $11.26 M(-5.1%) |
| Dec 2018 | $11.87 M(-52.2%) | $11.87 M(-1.9%) |
| Sep 2018 | - | $12.10 M(+20.2%) |
| Jun 2018 | - | $10.07 M(-0.4%) |
| Mar 2018 | - | $10.11 M(-59.3%) |
| Dec 2017 | $24.84 M(+390.1%) | $24.84 M(+143.3%) |
| Sep 2017 | - | $10.21 M(+121.3%) |
| Jun 2017 | - | $4.61 M(+1.1%) |
| Mar 2017 | - | $4.56 M(-10.0%) |
| Dec 2016 | $5.07 M(-62.3%) | $5.07 M(-40.1%) |
| Sep 2016 | - | $8.46 M(+61.8%) |
| Jun 2016 | - | $5.23 M(-11.8%) |
| Mar 2016 | - | $5.93 M(-55.9%) |
| Dec 2015 | $13.45 M(-34.3%) | $13.45 M(-28.2%) |
| Sep 2015 | - | $18.74 M(-4.7%) |
| Jun 2015 | - | $19.67 M(+11.3%) |
| Mar 2015 | - | $17.67 M(-13.7%) |
| Dec 2014 | $20.47 M(-47.3%) | $20.47 M(-9.7%) |
| Sep 2014 | - | $22.66 M(-28.7%) |
| Jun 2014 | - | $31.79 M(-22.0%) |
| Mar 2014 | - | $40.76 M(+4.9%) |
| Dec 2013 | $38.84 M(-10.0%) | $38.84 M(+0.1%) |
| Sep 2013 | - | $38.81 M(-13.8%) |
| Jun 2013 | - | $45.03 M(-4.2%) |
| Mar 2013 | - | $47.03 M(+9.0%) |
| Dec 2012 | $43.16 M(+11.5%) | $43.16 M(-18.8%) |
| Sep 2012 | - | $53.15 M(-19.1%) |
| Jun 2012 | - | $65.72 M(-6.8%) |
| Mar 2012 | - | $70.47 M(+82.1%) |
| Dec 2011 | $38.70 M(-18.2%) | $38.70 M(-5.8%) |
| Sep 2011 | - | $41.07 M(+66.9%) |
| Jun 2011 | - | $24.61 M(-6.6%) |
| Mar 2011 | - | $26.36 M(-44.3%) |
| Dec 2010 | $47.32 M(+82.9%) | $47.32 M(+0.2%) |
| Sep 2010 | - | $47.23 M(+282.8%) |
| Jun 2010 | - | $12.34 M(-32.5%) |
| Mar 2010 | - | $18.29 M(-29.3%) |
| Dec 2009 | $25.87 M(+8.9%) | $25.87 M(+8.5%) |
| Sep 2009 | - | $23.84 M(-1.8%) |
| Jun 2009 | - | $24.29 M(+54.9%) |
| Mar 2009 | - | $15.68 M(-34.0%) |
| Dec 2008 | $23.76 M | $23.76 M(-26.2%) |
| Sep 2008 | - | $32.19 M(-15.2%) |
| Jun 2008 | - | $37.96 M(-1.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2008 | - | $38.53 M(+9.0%) |
| Dec 2007 | $35.35 M(+82.5%) | $35.35 M(-9.0%) |
| Sep 2007 | - | $38.83 M(+54.6%) |
| Jun 2007 | - | $25.11 M(+50.1%) |
| Mar 2007 | - | $16.73 M(-13.6%) |
| Dec 2006 | $19.36 M(+239.1%) | $19.36 M(+89.9%) |
| Sep 2006 | - | $10.20 M(+20.9%) |
| Jun 2006 | - | $8.43 M(+49.5%) |
| Mar 2006 | - | $5.64 M(-1.2%) |
| Dec 2005 | $5.71 M(-67.7%) | $5.71 M(-66.9%) |
| Sep 2005 | - | $17.26 M(+36.8%) |
| Jun 2005 | - | $12.62 M(+21.3%) |
| Mar 2005 | - | $10.40 M(-41.1%) |
| Dec 2004 | $17.67 M(+6.6%) | $17.67 M(-37.6%) |
| Sep 2004 | - | $28.30 M(+98.8%) |
| Jun 2004 | - | $14.24 M(-33.9%) |
| Mar 2004 | - | $21.53 M(+29.9%) |
| Dec 2003 | $16.57 M(-49.2%) | $16.57 M(-20.0%) |
| Sep 2003 | - | $20.72 M(+54.8%) |
| Jun 2003 | - | $13.39 M(-9.1%) |
| Mar 2003 | - | $14.72 M(-54.8%) |
| Dec 2002 | $32.61 M(-25.4%) | $32.61 M(+69.6%) |
| Sep 2002 | - | $19.23 M(+30.4%) |
| Jun 2002 | - | $14.75 M(-46.6%) |
| Mar 2002 | - | $27.64 M(-36.8%) |
| Dec 2001 | $43.74 M(+165.4%) | $43.74 M(-33.0%) |
| Sep 2001 | - | $65.27 M(+46.2%) |
| Jun 2001 | - | $44.64 M(+0.4%) |
| Mar 2001 | - | $44.45 M(+169.7%) |
| Dec 2000 | $16.48 M(+48.5%) | $16.48 M(-16.7%) |
| Sep 2000 | - | $19.79 M(-45.0%) |
| Jun 2000 | - | $35.95 M(-46.3%) |
| Mar 2000 | - | $66.98 M(+503.4%) |
| Dec 1999 | $11.10 M(-18.4%) | $11.10 M(-0.9%) |
| Sep 1999 | - | $11.20 M(+0.9%) |
| Jun 1999 | - | $11.10 M(+13.3%) |
| Mar 1999 | - | $9.80 M(-27.9%) |
| Dec 1998 | $13.60 M(+11.5%) | $13.60 M(+9.7%) |
| Sep 1998 | - | $12.40 M(+22.8%) |
| Jun 1998 | - | $10.10 M(-19.8%) |
| Mar 1998 | - | $12.60 M(+3.3%) |
| Dec 1997 | $12.20 M(-3.2%) | $12.20 M(+82.1%) |
| Sep 1997 | - | $6.70 M(+11.7%) |
| Jun 1997 | - | $6.00 M(-38.1%) |
| Mar 1997 | - | $9.70 M(-23.0%) |
| Dec 1996 | $12.60 M(+75.0%) | $12.60 M(+200.0%) |
| Sep 1996 | - | $4.20 M(-30.0%) |
| Jun 1996 | - | $6.00 M(+46.3%) |
| Mar 1996 | - | $4.10 M(-43.1%) |
| Dec 1995 | $7.20 M(+213.0%) | $7.20 M(-79.8%) |
| Sep 1995 | - | $35.70 M(+363.6%) |
| Jun 1995 | - | $7.70 M(+670.0%) |
| Mar 1995 | - | $1.00 M(-56.5%) |
| Dec 1994 | $2.30 M(+91.7%) | $2.30 M(+4.5%) |
| Sep 1994 | - | $2.20 M(+144.4%) |
| Jun 1994 | - | $900.00 K(+50.0%) |
| Mar 1994 | - | $600.00 K(-50.0%) |
| Dec 1993 | $1.20 M(-88.1%) | $1.20 M(-96.4%) |
| Sep 1993 | - | $33.60 M(+62.3%) |
| Jun 1993 | - | $20.70 M(+7.8%) |
| Mar 1993 | - | $19.20 M(+90.1%) |
| Dec 1992 | $10.10 M(+1920.0%) | $10.10 M(+1920.0%) |
| Dec 1991 | $500.00 K(-80.0%) | $500.00 K(-80.0%) |
| Dec 1990 | $2.50 M | $2.50 M |
FAQ
- What is Fresh Tracks Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Fresh Tracks Therapeutics?
- What is Fresh Tracks Therapeutics annual cash & cash equivalents year-on-year change?
- What is Fresh Tracks Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Fresh Tracks Therapeutics?
- What is Fresh Tracks Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Fresh Tracks Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of FRTX is $10.87 M
What is the all time high annual cash & cash equivalents for Fresh Tracks Therapeutics?
Fresh Tracks Therapeutics all-time high annual cash & cash equivalents is $47.32 M
What is Fresh Tracks Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, FRTX annual cash & cash equivalents has changed by +$2.19 M (+25.21%)
What is Fresh Tracks Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of FRTX is $10.87 M
What is the all time high quarterly cash and cash equivalents for Fresh Tracks Therapeutics?
Fresh Tracks Therapeutics all-time high quarterly cash and cash equivalents is $70.47 M
What is Fresh Tracks Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, FRTX quarterly cash and cash equivalents has changed by -$1.15 M (-9.58%)